Has FDA approved this cancer vaccine?
Today, to register the vaccine RESAN, it is necessary
to conduct clinical trials for each type of tumors, against which
the vaccine works. For example, in order to under go clinical trials
of the vaccine against prostate cancer according to the standards
of GCP, The Cancer Research Institute allots 450 000 $ for a 3 year-
grant. That means, for holding clinical trials of vaccine in concern
with breast cancer we need another 450 000 $, and for ovary cancer
450 000 $ more and so on for each other types of tumors.
Annually The Cancer Research Institute finances altogether
3 projects on clinical trials of anticancer vaccines. SRE RESAN did
submit all the necessary documents to The Cancer Research Institute
(681 Fifth Avenue New York, NY 10022-4209) for the grant of 15 April
2001 round to hold the clinical trials of vaccine RESAN. After 4 months
the project was rejected with an explanation that CRI was in shortage
of finance.
In fact, in spite of the excessive demands in the
cancer treatment, the FDA has not approved any cancer vaccines for
use as a standard treatment so far.
Can a single vaccine (RESAN) be effective
against many different tumors? |
In many people may arise the question: how could
a single vaccine may be effective in such broad types of tumors? They
think that usually one vaccine can work against only one type of disease.
Such point of view is not always correct. For example, in 2000 the
European Agency for the Evaluation of Medical Products – EMA
has approved an administration of a new vaccine – Hexavac®
elaborated by the company PASTEUR MERIEUX MSD. This combined vaccine
is used for preventing a group of infections – diphtheria, tetanus,
hooping-cough, poliomyelitis, hepatitis and hemophilic infection type
b. In this way the vaccine works against 6 different infections and
is released at a dose of 0.5 ml ready for injections.
Moreover, the immune system is capable to response
against thousand different antigens at a time, therefore there is
nothing supernatural that the vaccine RESAN helps to develop the immune
answer against 40 different tumor antigens.
Would the NEW immunotherapy replace the traditional chemo or radiotherapy?
Today unfortunately the traditional methods- chemo
and radiotherapy still dominate in the field of cancer treatment.
But as time passes we move forward and the controversy between the
supporters and opponents of the immunological aspects in the genesis
and treatment of the malignant tumors is already out of subject for
further discussion, as it was the dispute with rather narrow minded,
conservative and bureaucratic opponents. What so ever, it is not meant
that one should rush to a conclusion and immediately hand over all
the former methods of cancer treatment into archive, on the other
hand, it is absolutely not correct to convert them into an authoritative
doctrines. Taking into account those numerous factors which define
the successes in treatment and prevention of relapses of malignant
tumors, it is absolutely fare to diametrically oppose, beforehand,
the obvious out-of-date, palliative and little promising traditional
medical programs turning into a standard harsh pattern scheme of modern
cancer treatment.
More about the problems of
tradional methods...
|
